Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)
NCT ID: NCT05629065
Last Updated: 2025-08-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
800 participants
INTERVENTIONAL
2022-11-28
2028-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Serious Illness Communication Project
NCT01786811
Seeking Informed Consent to Phase I Cancer Clinical Trials: Identifying Oncologists'Communication Styles
NCT00582192
Improving Goals of Care Discussion in Advanced Cancer Patients
NCT02374255
Care For The Cancer Caregiver: A Meaning-Based Workshop To Help Manage Caregiver Burden
NCT02250911
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
NCT04867850
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Identified participants and clinicians will be randomized into 1 or 4 groups.
* Nudge to patient and clinician
* Nudge to patient only
* Nudge to clinician only
* No nudge.
The expected enrollment is approximately 800 participants.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Both patient and clinician receive a nudge
* Patient nudge consists of a letter and SHARE questionnaire
* Clinician "nudge" email encouraging discussion to initiate discussion on SIC
Clinician Nudge Email
-Clinician "nudge" email encouraging discussion to initiate discussion on SIC at next visit
Patient Nudge Letter and Share questionaire
Involves patient nudge consists of a letter and SHARE questionnaire
\- patient nudge is a letter and a SHARE questionnaire encourages the participant to complete the SHARE questionnaire, which asks questions about the participants goals and preferences around cancer care, and discuss the questionnaire with their oncology clinician at the next visit.
Neither the patient nor clinician receive a nudge
Standard Care
No interventions assigned to this group
Patient receives a nudge but not the clinician
-Patient nudge consists of a letter and SHARE questionnaire
Patient Nudge Letter and Share questionaire
Involves patient nudge consists of a letter and SHARE questionnaire
\- patient nudge is a letter and a SHARE questionnaire encourages the participant to complete the SHARE questionnaire, which asks questions about the participants goals and preferences around cancer care, and discuss the questionnaire with their oncology clinician at the next visit.
Clinician receives a nudge but not the patient
-Clinician "nudge" email encouraging discussion to initiate discussion on SIC
Clinician Nudge Email
-Clinician "nudge" email encouraging discussion to initiate discussion on SIC at next visit
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clinician Nudge Email
-Clinician "nudge" email encouraging discussion to initiate discussion on SIC at next visit
Patient Nudge Letter and Share questionaire
Involves patient nudge consists of a letter and SHARE questionnaire
\- patient nudge is a letter and a SHARE questionnaire encourages the participant to complete the SHARE questionnaire, which asks questions about the participants goals and preferences around cancer care, and discuss the questionnaire with their oncology clinician at the next visit.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Breast Oncology Clinic
* Gastrointestinal Oncology Clinic
* Genitourinary Oncology Clinic
* Gynecologic Oncology Clinic
* Thoracic Oncology Clinic
Exclusion Criteria
* Patients who have previously been randomized in this trial (e.g., the patient is encountering a poor-prognosis node for the second time during the trial period)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dana-Farber Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christopher Manz, MD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christopher Manz, MD
Role: PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22-501
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.